Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome

Ivan Negara,Ciprian Tomuleasa,Sanda Buruiana,Dimitar G. Efremov

DOI: https://doi.org/10.3390/cancers16122170

2024-06-08

Cancers

Abstract:Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy and a heterogeneous entity comprised of several biologically distinct subtypes. Recently, novel genetic classifications of DLBCL have been resolved based on common mutational patterns indicative of distinct pathways of transformation. However, the complicated and costly nature of the novel classifiers has precluded their inclusion into routine practice. In view of this, the status of the TP53 gene, which is mutated or deleted in 20–30% of the cases, has emerged as an important prognostic factor for DLBCL patients, setting itself apart from other predictors. TP53 genetic lesions are particularly enriched in a genetic subtype of DLBCL that shares genomic features with Richter Syndrome, highlighting the possibility of a subset of DLBCL arising from the transformation of an occult chronic lymphocytic leukemia-like malignancy, such as monoclonal B-cell lymphocytosis. Patients with TP53-mutated DLBCL, including those with Richter Syndrome, have a particularly poor prognosis and display inferior responses to standard chemoimmunotherapy regimens. The data presented in this manuscript argue for the need for improved and more practical risk-stratification models for patients with DLBCL and show the potential for the use of TP53 mutational status for prognostication and, in prospect, treatment stratification in DLBCL.

oncology

What problem does this paper attempt to address?

The paper attempts to address the role and molecular subtype classification of the TP53 gene in Diffuse Large B-Cell Lymphoma (DLBCL) and its association with Richter Syndrome.

Specifically:
1. **Molecular Subtype Classification**: The paper summarizes recent advances in molecular and genetic classification algorithms for DLBCL and discusses the impact of these classifications on disease prognosis and treatment strategies.
2. **Role of TP53**: The paper explores the significance of TP53 gene mutations and deletions in DLBCL, particularly in the context of Richter Syndrome, and emphasizes the importance of TP53 gene status as a prognostic factor for DLBCL patients.
3. **Clinical Applications**: The paper proposes the need for improved risk stratification models and demonstrates the potential of using TP53 mutation status for prognostic assessment and treatment stratification, especially in patients with poor response to standard chemoimmunotherapy.

Overall, the paper aims to promote the development of more precise diagnostic and therapeutic approaches through an in-depth analysis of the role of the TP53 gene in DLBCL.